ACHILLION PHARMACEUTICALS $7.64

down -0.10


23/5/2013 04:23 PM  |  NASDAQ : ACHN  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 6% - ACHN has underperformed the S&P 500 by 19%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Mid-Day Market Update: SolarCity Wins Big, SunPower Continues its Fall

    Benzinga

  2. Bank of America Merrill Lynch Reiterates Buy Rating, $13 PT on ...

    Benzinga

  3. Gilead Hep C Drug Meets Expectations In Phase 3 Trial

    Investors Business Daily

  4. Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes ...

    Benzinga

  5. Achillion Provides Update on Clinical HCV Development Programs, ...

    Benzinga

  6. Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus

  7. Achillion Pharmaceuticals Says Farewell to Single Digits

    By SchaeffersResearch

  8. Benzinga's Top Pre-Market Gainers

    Benzinga

  9. Achillion Pharmaceuticals (ACHN) Up 14.3% After Upgrades

    At Market Intelligence Center

  10. UPDATE: Deutsche Bank Initiates Coverage on Achillion ...

    Benzinga

  11. UPDATE: Deutsche Bank Initiates Buy on Achillion Pharmaceuticals

    Benzinga

  12. Benzinga's Top Pre-Market Gainers

    Benzinga

  13. UPDATE: Piper Jaffray Reiterates Overweight Rating, Lowers PT on ...

    Benzinga

  14. Achillion to Raise $41.8 Million Through Registered Direct Offering

    Benzinga

  15. Speculator Raises the Bullish Stakes on Achillion Pharmaceuticals

    By SchaeffersResearch

  16. Bristol-Myers' $2.5 Billion Acquisition of Inhibitex: Oh, Well

    YCharts

  17. Idenix's FDA Trouble Shakes Up Hep C Drug Stocks

    Investors Business Daily

  18. Benzinga's Top Upgrades

    Benzinga

  19. Health Care Sector Wrap

    FOXBusiness

  20. Achillion Announces Resignation of Chief Medical Officer

    Benzinga

  21. UPDATE: UBS Investment Research Upgrades Achillion to Neutral; ...

    Benzinga

  22. UPDATE: Bank of America Raises Actuant's PT

    at Benzinga

  23. Piper Jaffray: Achillion Pharmaceuticals Ended 2011 with $80M Cash

    at Benzinga

  24. Gilead Sees Hep C Setback

    at IBD

  25. Gilead Falls On Disappointing Hep C Drug Data; Analysts Remain Bullish

    at Benzinga

  26. Achillion Pharmaceuticals Announces Virology Profile Following ...

    at Benzinga

  27. Achillion Pharmaceuticals (ACHN) Loses 7.9% Despite Merger Speculation

    At Market Intelligence Center

  28. Benzinga's M&A Chatter for Wednesday February 8, 2012

    at Benzinga

  29. Benzinga's Top Pre-Market Losers

    at Benzinga

  30. Financial Breakfast: Morning News Summary for February 07, 2012

    at Benzinga

  31. UPDATE: Bank of America Downgrades Achillion Pharmaceuticals to ...

    at Benzinga

  32. Benzinga's M&A Chatter for Thursday February 2, 2012

    at Benzinga

  33. Benzinga's M&A Chatter for Tuesday January 24, 2012

    at Benzinga

  34. Afternoon Movers; Negative Euro News

    at Benzinga

  35. Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster ...

    at GuruFocus

  36. Benzinga's M&A Chatter for Friday January 20, 2012

    at Benzinga

  37. End-of-Day Market Summary for January 20, 2012

    at Benzinga

  38. Afternoon Movers; Markets Moved Sideways

    at Benzinga

  39. Negative Article by Seeking Alpha on Achillion

    at Benzinga

  40. Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM

    at GuruFocus

  41. Achillion Pharmaceuticals Inc. (ACHN) CEO and President Michael D ...

    at GuruFocus

  42. Achillion Pharmaceuticals Inc. (ACHN) CEO and President Michael D ...

    at GuruFocus

  43. Achillion Pharmaceuticals Inc. (ACHN) SVP and CFO Mary Kay Fenton ...

    at GuruFocus

  44. End-of-Day Market Summary for January 10, 2012

    at Benzinga

  45. Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target?

    at Benzinga

  46. Afternoon Movers; Markets Moved Higher

    at Benzinga

  47. Just What The Doctor Ordered: 4 ETFs For Biotech M&A

    at Benzinga

  48. Forget Dendreon, Inhibitex is the New Biotech Success Story

    at Benzinga

  49. Achillion Pharmaceuticals

    at IBD

  50. Best Biotech Stocks of 2011

    at Benzinga
People viewing ACHN also viewed: , , , , , ,
Marketplace
Trading Center